New York, October 8th / PRNewswire / -- Pomerantz LLP represents and is acting on behalf of the investors of Tyra Biosciences, Inc ("Tyra" or "the Company") (Nasdaq ticker: TYRA). The firm advises investors to contact Danielle Peyton at the email address [ email protected ], the phone number is 646-581-9980, extension 7980.
This investigation involves whether Tyra and some of its senior executives and/or directors are engaged in securities fraud or other illegal business practices.
[Click here to learn how to join a class action]
On September 9th, Tyra issued a press release.Announced the preliminary results of SURF302.SURF302 is a phase II study that evaluates the use of oral dabogratinib in patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG IR NMIBC) with FGFR3 mutations. The company stated that these data indicate favorable safety profiles, however, in the two dose groups of 60 milligrams once daily (QD) and 50 milligrams once daily (QD), 14% and 9% of the subjects, respectively, experienced grade 3 adverse events during treatment.
Affected by this news, the stock price of Tyra fell by $4.72 on September 9, 2026, a decrease of 17.66%, closing at $22.01 per share.
Pomerantz LLP has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, and is recognized as one of the leading law firms in the fields of corporate law, securities law, and class action litigation. The firm was founded by the late Abraham L and Pomerantz, the latter being known as the "dean" of class action lawyers, and Pomerantz was also a pioneer in the field of securities class actions. More than 85 years have passed since its establishment, and Pomerantz continues to uphold the traditions founded by its founders, fighting for the rights of victims of securities fraud, breach of fiduciary duty, and corporate misconduct. The firm has represented class members in obtaining compensation awards totaling millions of dollars. For more details, please see www.pomlaw.comMandatory requirements:
Lawyer advertisement. Past results do not guarantee similar outcomes in the future.
Contact Information:
Danielle PeytonPomerantz LLP646-581-9980 ext . 7980
